November 2nd, 2011
FDA Approves Abbott’s Xience Prime Drug-Eluting Stent
Larry Husten, PHD
Abbott announced on Tuesday that it had received FDA approval for its Xience Prime everolimus-eluting stent. The cobalt chromium stent is designed to be delivered more easily to complex lesions and will be available in long lengths up to 38 mm. Approval of Xience Prime was based on the SPIRIT Prime clinical trial, an open-label registry […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?